Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
Novartis Pharmaceuticals
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- VICTORION-2P
- status
- ACTIVE_NOT_RECRUITING
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 17004
- sponsor
- Novartis Pharmaceuticals
- conditions
- Atherosclerotic Cardiovascular Disease
- interventions
- DRUG: Inclisiran sodium 300 mg; DRUG: Placebo
- start date
- 2021-11-23
- start date type
- ACTUAL
- primary completion date
- 2027-05-10
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT05030428
- Published
- Sep 1, 2021
- Updated
- Aug 25, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT05030428
- Categories
- Atherosclerotic Cardiovascular Disease
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials